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Although renal failure is one of the known comorbidities associated with rapid progression of aortic stenosis, it is unclear
whether hemodialysis alters the progression of prosthetic aortic valve stenosis. We describe a 79-year-old female who underwent
bioprosthetic aortic valve replacement 8 years ago with stable prosthetic valve area for the initial 6 years. In the last two years,
coinciding with the initiation of maintenance hemodialysis, she developed progressive prosthetic valve stenosis to the point of
clinicaldecompensation.She underwent a second prosthetic aorticvalve replacement with symptom resolution.This casesuggests
that circulating milieu in end-stage renal failure and dialysis can accelerate the progression of prosthetic aortic valve stenosis.
Morefrequent clinicalfollowupandsurveillance echocardiogram for dialysispatients withbioprosthetic aortic valvemayfacilitate
timely management of valvular stenosis.
1.Introduction
The natural history of aortic stenosis can be aﬀected by a
number ofcomorbidities.Althoughrenalfailure is oneofthe
knowncomorbiditiesforrapidprogression ofaorticstenosis,
it is unclear whether hemodialysis alters the development
and progression of prosthetic aortic valve stenosis. We de-
scribe a patient with a bioprosthetic aortic valve who ac-
quired accelerated aortic stenosis following the initiation of
hemodialysis for end-stage renal failure.
2.CaseReport
A 79-year-old female was admitted for dyspnea with hypoxia
in October 2010. She had longstanding history of hyper-
tension, hyperlipidemia, and chronic kidney dysfunction. In
2002, she underwent aortic valve replacement with a 23mm
Carpentier-Edward tissue aortic valve for critical aortic
stenosis related to bicuspid aortic valve. In 2008, she was ini-
tiated on hemodialysis for end-stage renal failure secondary
to biopsy-proven hypertensive nephrosclerosis. She received
dialysis via a right internal jugular tunneled dialysis catheter.
Arterial-venous ﬁstula was not created per her request. She
was on a stable medical regimen of metoprolol, gemﬁbrozil,
ezetimibe, allopurinol, and aspirin. For her end-stage renal
failure, she was maintained on calcium acetate 1334mg with
each meal as well as paricalcitol 7.5mcg and darbepoetin
with hemodialysis. Since February of 2010, she began to
experience progressive worsening dyspnea with notable or-
thopnea, paroxysmal nocturnal dyspnea, and decreasing
exercise tolerance. Transthoracic echocardiograms (see Sec-
tion 3) revealed progressive worsening prosthetic valve
stenosis.
Physical examination on admission showed blood pres-
sure 94/54mmHg, respiratory rate 30/minute, oxygen satu-
ration 93% on 70% oxygen via a facemask, pulse 86/minute,
and diﬀuse crackles in bilateral lung ﬁelds. She had dimin-
ished bilateral carotid upstroke and a 4/6 systolic ejection
murmur across the precordium associated with soft aortic
component of the second hearts o u n d .T h e r ew a sn ol o w e r
extremity edema. Laboratory results included hemoglobin
11g/dL, leukocyte count 10.6×109/L, sodium 141mmol/L,
potassium 5.5mmol/L, bicarbonate 21mmol/L, and crea-
tinine 5.4mg/dL. A chest X-ray showed ﬂorid pulmonary2 International Journal of Nephrology
edema. She was provisionally diagnosed with ﬂuid overload
and heart failure.
3.Imaging Studies
Transthoracic echocardiogram was performed, which show-
ed severe prosthetic aortic valve stenosis. On review of prior
echocardiograms, there was a rapid progression of the valve
stenosis along with elevated serum calcium-phosphate prod-
uct levels following the initiation of hemodialysis (Figure 1
and Table 1).
4.ClinicalFollowup
A coronary angiogram was performed which showed an
approximately 30% obstruction of left anterior descending
artery in addition to the aortic stenosis. She subsequently
underwent a second aortic valve replacement with a 23mm
Mitroﬂow bioprosthetic valve and coronary artery bypass
surgery with left internal mammary artery graft to the left
anterior descending artery. Prior to the operation, an option
of mechanical valve versus tissue valve was discussed. A
decision to proceed with another tissue valve was made on
the basis of her age, risks associated with chronic anticoagu-
lation,andherpreference.Intraoperatively,herbioprosthetic
aortic valve was visibly noted to be heavily calciﬁed, and
the cusps were retracted with small vegetations attached
to them. There was no cusp tear, thrombus, or ﬁbrous
pannus ingrowth. Following the surgery, her systemic blood
pressure improved (110–130/70–80mmHg) and respiratory
symptoms resolved. She was discharged from the hospital,
and remained asymptomatic at one-month followup.
5.Discussion
We present a patient who developed accelerated stenosis in
the bioprosthetic aortic valve coincident with the initiation
of hemodialysis, suggesting that the circulating milieu in
end-stage renal failure and dialysis can adversely aﬀect the
progression of prosthetic aortic valve stenosis.
Aortic valve stenosis, deﬁned as a reduction in the aortic
valve area (normal range 2–4cm2) leading to an increase in
transvalvular jet velocity (>2.6m/s) and decrease in cardiac
output, is the most common valvular abnormality in both
the general population and patients with renal failure. It is
the most frequent cause of death associated with valvular
heart disease and an independent risk factor for death in
dialysis patients [1–4]. Aortic stenosis can be caused, alone
or in combination, by congenital bicuspid valve or acquired
valvular degenerative calciﬁcation related to longstanding
hypertension, hyperlipidemia, calciﬁc disease, and chronic
inﬂammatory conditions such as rheumatic disease [5]. In
recent decades, with increases in life expectancy, the major
cause of aortic stenosis has shifted from congenital valvular
abnormality, that is, bicuspid aortic valve, to acquired
degenerative valvular calciﬁcation [1, 6, 7].
As aortic stenosis is known to progress, regular monitor-
ing to facilitate timely treatment before irreversible myocar-
dial damage is lifesaving [1, 2]. In practice, progression of
aortic stenosis is routinely monitored by clinical observation
and by echocardiographic examination, which determines
the aortic valve area, mean transvalvular pressure gradient,
and maximal jet velocity. The current practice guidelines for
monitoring aortic stenosis are to perform periodic transtho-
racic echocardiography, every 3 to 5years for mild aortic
stenosis (deﬁned as a valve area of 1.2–1.5cm2,m e a ng r a d i -
ent of <25mmHg, or jet velocity of 2.5–3.0m/s), 1 to 2years
for moderate stenosis (valve area of 0.7–1.2cm2,m e a n
gradient of 25–40mmHg, or jet velocity of 3.0-4.0m/s),
and yearly for severe stenosis (valve area of <0.7cm2,m e a n
gradientof>40mmHg, orjet velocity of>4.0m/s) [8, 9]. On
average, aortic valve area decreases by 0.05–0.1cm2/year, jet
velocity increases by approximately 0.3m/s/year, and mean
pressure gradient increases by approximately 7mmHg/year
[8].
Hemodialysis has been shown to correlate with an
increased prevalence (40–52%) and a rapid progression of
native aortic valve stenosis [1, 3, 8, 10–12]. In a retrospective
study of 110 patients on maintenance hemodialysis, Ure na
et al. found an increased incidence of aortic stenosis and
an accelerated reduction of aortic valve area from 1.24 to
0.66cm2/m2 of body surface area in 16.8 ± 1.9months[3].
Such changes correspond to an average reduction in the
valve area of 0.23cm2/year, a progression rate over two times
that of the general population (0.05–0.1cm2/year) [3, 8, 13].
Perkovic et al. provided further support in a retrospective
case-control study [14]. They compared progression of
aortic stenosis in dialysis patients to sex-matched nondialysis
individuals, 28 and 56 patients in each group, respectively.
They found an average decrease in the aortic valve area of
0.19cm2/yearand increase in thepeak transvalvular gradient
of 4.9mmHg/year in the dialysis patients, a signiﬁcantly
rapid progression compared to the nondialysis patients,
0.07cm2/year and 2.5mmHg/year, respectively. Recently, a
study by Zentner et al. showed that when matched for
aortic stenosis severity at the study entry, dialysis patients,
compared to nondialysis patients, had a decreased event-free
survival (eventdeﬁned as death or aortic valve replacement),
once again correlating to accelerated aortic stenosis in
dialysis patients [15].
The pathophysiology underlying the rapid progression
of aortic stenosis in dialysis patients has not been fully elu-
cidated. A reduced aortic valve area at baseline, preexisting
valvular calciﬁcation, and high levels of circulating calcium-
phosphate product and parathyroid hormone have all been
proposed to contribute to the progression of stenosis [3, 16–
19].Data onprogression ofprostheticaortic valvestenosis in
renal failure patients are scarce. Only two case reports were
found in the literature. Bradley et al. described a hemodial-
ysis patient who received a bioprosthetic (heterograft)
aortic valve for native bacterial valve endocarditis. About
15 months later, the patient developed symptoms of aortic
stenosis. Echocardiography showed a critical prosthetic
valve stenosis with heavy valvular calciﬁcation. The patient
underwent a second tissue valve (Bjork-Shiley prosthesis)International Journal of Nephrology 3
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Figure1:(a)showsshort-axisimagesoftheaorticvalveprosthesis.(A)istheaorticvalveprosthesis5yearsafterimplantationdemonstrating
minimal calciﬁcation and thin, barely visible, leaﬂets. Shown on (B) is the prosthetic aortic valve about 2-years after beginning dialysis
demonstratingheavy leaﬂet calciﬁcation(arrows).(b) showsthe aortic valve prosthetic mean gradient by spectral continuous wave Doppler
echocardiography demonstratinga normalgradient5years after implantation(A)anda markedlyincreased gradientshortlyafterbeginning
dialysis(B),correspondingto the imagesin(a).(c)showsthe intraoperative transesophagealechocardiographic imagesofthe stenoticaortic
valve prosthesis at the time of the second aortic valve operation. Short-axis image on the left (A) and long-axis image on the right (B)
demonstrate marked leaﬂet calciﬁcation,thickening, and severe stenosis.4 International Journal of Nephrology
Table 1: Summary data of serial echocardiography and serum calcium and phosphate concentration.
Test Date
Transthoracic echocardiogram Calcium-phosphate
Aortic valve area (cm2) Transvalvular gradient (mmHg) Velocity (m/sec) Product (calcium ×
phosphate) (mg/dL)
Sept. 2002 0.73 56 4.7
Oct. 2002 1st aortic valve replacement operation 35.7 (9.4 ×3.8)
Oct. 2004 1.78 22 3.6
Oct. 2006 ∗ 17 2.8
July 2007 1.87 19 3.0
April 2008 1.74 16 2.7
May 2008 Commencement of dialysis 64.8 (7.9 ×8.2)
March 2010 0.88 40 4.3
April 2010 ∗ 49 4.3 53.9 (9.3 ×5.8)
Sept. 2010 0.73 74 5.1 51.9 (9.1 ×5.7)
Oct. 2010 2nd aortic valve replacement operation 47.2 (8.9 ×5.3)
Nov. 2010 2.08 21
∗: Unavailable (missing data).
replacement that resulted in symptom resolution [20]. In
another report by Hahn and Maze a hemodialysis patient
who had a bioprosthetic aortic valve replacement for native
calciﬁc aortic stenosis developed symptoms of heart failure
due to critical prosthetic valve stenosis only 20months after
the valve replacement surgery. The patient subsequently had
a second St. Jude mechanical valve replacement with reso-
lution of the symptoms [21]. The progression of prosthetic
valve stenosis in our patient seemed to follow the pattern of
these reported cases. Her advanced age, possible subclinical
prosthetic valve infection (suggested by small vegetations
on the resected valve), elevated calcium-phosphate product
level,asshown inTable1,andchronicdialysiscouldallbethe
potential factors contributing to the accelerated progression
of bioprosthetic valve stenosis. We speculate that per-
haps if the reversible factors, that is, calcium-phosphorous
product and subclinical infection, were more tightly con-
trolled, the rate of her valve degeneration might have been
tempered.
Whether dialysis patients are more suited for having bio-
prosthetic or mechanical valve replacement remains unclear.
Becausecalciﬁcstenosis ofprostheticvalveisknown to occur
almost exclusivelywith bioprostheticvalves, it was advocated
that for dialysis patients mechanical valve might be a more
appropriatechoice.However,threeretrospective studieshave
challenged this notion. Kaplon et al. conducted an initial
study on 42 chronic hemodialysis patients who underwent
mitral and aortic valve replacements; 17 received mechanical
valves and 25 bioprosthesis. Patient survival at 3 and 5years
between two groups was similar [22]. Subsequently, Chan
et al. studied 69 dialysis patients with valve replacement
surgery; 47 had aortic valve replacement, 33 bioprosthetic
and 14 mechanical valves. That founds the 5-year of freedom
from valve related complications were similar for bio-
prosthetic and mechanical valves [23]. Bioprosthetic valves
were more prone to calciﬁcation while mechanical valves
had increased risks of valve related thrombosis, throm-
boembolism, and hemorrhage due to anticoagulation. It
seems that the beneﬁt of less prosthetic calciﬁcation with
mechanical valves is oﬀset by their thrombogenic and
anticoagulation associate complications. Similarly, a recent
study by Tanaka et al. found no signiﬁcant diﬀerence in late
outcomes (an average followup of 42 ± 31 months) between
bioprosthetic (n = 22) and mechanical (n = 51) aortic valve
replacement in dialysis patients [24]. Furtherstudy is needed
to conﬁrm these ﬁndings.
This case has important clinical implications. Chronic
kidneydiseasepopulationisincreasing,soisthedialysispop-
ulation. Aortic stenosis is the most common valvular abnor-
mality among dialysis patients and is much more prevalent
than in the general population. Although the occurrence
of rapid prosthetic valve stenosis appears sporadic, with
increasing number of dialysis patients, it is important to
investigate the underlying risk factors for this phenomenon
so that at-risk patients could be identiﬁed and preventive
measures implemented. Moreover, as untreated aortic steno-
sis can be fatal, the recognition that prosthetic aortic valve
may become rapidly stenotic in dialysis patients should
increase alertness of this diagnostic possibility, leading to
an appropriate investigation (echocardiography in this case)
and timely treatment, thereby avoiding irreversible cardiac
damage and death.
In summary, we present a patient with accelerated pro-
gression of prosthetic aortic valve stenosis following the ini-
tiation of dialysis. Echocardiography is essential in making
the diagnosis. Although further study is needed to better
understand the natural history of prosthetic valve stenosis in
dialysis patients, this case suggests that, in dialysis patients
with prosthetic aortic valve, the valve stenosis may recur at
an accelerated pace. A tailored approach with more frequent
clinical followup and surveillance echocardiogram may be
necessary.International Journal of Nephrology 5
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